The biotechnology company provides an update on its ongoing Phase I clinical trial for its HG-CT-1 therapy, including DSMB clearance to advance to the next dose level and the initiation of pediatric patient recruitment.
The biotechnology company has received clearance to enroll children and adolescents in its ongoing HG-CT-1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
The biopharmaceutical firm reports promising clinical progress in its Phase I trial for AML treatment. However, financial challenges loom with doubled losses and urgent funding needs.
The biotechnology company has signed a letter of intent with a leading Estonian cell therapy firm to advance the commercialization of its HG-CT-1 CAR-T therapy for relapsed or refractory acute myeloid leukemia.
The healthcare company has announced changes to its major shareholders.
The biotechnology company reports successful treatment of a third patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has been invited to present at the upcoming DCNY Summit, a prestigious event connecting policymakers, investors, and innovators.
The biotechnology company has announced a manufacturing partnership to advance its lead CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has raised £235,799 through the exercise of warrants, strengthening its balance sheet without significant dilution to shareholders.
The biotechnology company has raised £450,000 through the exercise of warrants, but at a steep 73.4% discount to the previous closing price, suggesting low market confidence.